» Articles » PMID: 35023092

Genotypic and Clinical Analysis of a Thalassemia Major Cohort: An Observational Study

Overview
Date 2022 Jan 13
PMID 35023092
Authors
Affiliations
Soon will be listed here.
Abstract

Thalassemia major (TM) is a hereditary disease caused by defective globin synthesis. Because of the significant increase in life expectancy, these patients are suffering from various health conditions, including endocrinopathies and low bone mineral density. The aim of the present study was to investigate the correlation between clinical and biochemical parameters as well as to identify possible relations in a genotype to phenotype pattern. Sixty-four patients with TM (32 men and 32 women) participated in a cross-sectional study design. The patients were recruited from "Aghia Sofia" Children's Hospital. Clinical and biochemical parameters were evaluated as well as specific mutations were identified. We have found significant correlations between biochemical parameters and iron chelation, hormone replacement treatment as well as TM genotype and hematocrit and T-score. To conclude, the current study showed that clinical parameters of TM patients correlate significantly with both biochemical factors and genotypical patient parameters. Our present study showed that there is a connection between genotype and phenotype as, for example, the identified relation between hematocrit and T-scores and TM-specific mutations. This connection indicates that there is still much more to learn about the role of mutations not only in the disease itself but also in the underlying comorbidities.

Citing Articles

Assessment of cardiac iron deposition and genotypic classification in pediatric beta-thalassemia major: the role of cardiac MRI.

Zhang S, Zhao W, Sun L, Liang G, Wang X, Zeng H BMC Med Imaging. 2025; 25(1):31.

PMID: 39885407 PMC: 11783902. DOI: 10.1186/s12880-025-01567-7.


Beta-Thalassemia and Male Infertility: Unraveling the Oxidative Stress Connection-An Up-to-Date Review.

Roidos C, Batakoias C, Symeonidis E, Kaltsas A, Tzikoulis V, Tsampoukas G Diagnostics (Basel). 2025; 14(24.

PMID: 39767150 PMC: 11727083. DOI: 10.3390/diagnostics14242789.


New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.

Carsote M, Vasiliu C, Trandafir A, Albu S, Dumitrascu M, Popa A Diagnostics (Basel). 2022; 12(8).

PMID: 36010271 PMC: 9406368. DOI: 10.3390/diagnostics12081921.

References
1.
Cousens N, Gaff C, Metcalfe S, Delatycki M . Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet. 2010; 18(10):1077-83. PMC: 2987452. DOI: 10.1038/ejhg.2010.90. View

2.
Lee Y, Kim H, Lee K, Park S, Song S, Seong M . Recent progress in laboratory diagnosis of thalassemia and hemoglobinopathy: a study by the Korean Red Blood Cell Disorder Working Party of the Korean Society of Hematology. Blood Res. 2019; 54(1):17-22. PMC: 6439293. DOI: 10.5045/br.2019.54.1.17. View

3.
Goh S, Lee Y, Bhanu N, Cam M, Desper R, Martin B . A newly discovered human alpha-globin gene. Blood. 2005; 106(4):1466-72. PMC: 1895206. DOI: 10.1182/blood-2005-03-0948. View

4.
Karponi G, Zogas N . Gene Therapy For Beta-Thalassemia: Updated Perspectives. Appl Clin Genet. 2019; 12:167-180. PMC: 6765258. DOI: 10.2147/TACG.S178546. View

5.
Weatherall D, Clegg J . Genetic disorders of hemoglobin. Semin Hematol. 1999; 36(4 Suppl 7):24-37. View